A Phase 1/2 Trial of Pembrolizumab in Combination With Blinatumomab in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Latest Information Update: 07 May 2024
At a glance
- Drugs Blinatumomab (Primary) ; Pembrolizumab (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- 01 May 2024 Planned End Date changed from 15 Apr 2024 to 30 Oct 2024.
- 01 May 2024 Planned primary completion date changed from 15 Apr 2024 to 30 Oct 2024.
- 13 Dec 2022 Interim Results(As of June 15 ,2022 N=15) assessing safety and tolerability of Pembrolizumab Combined with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia presented at the 64th American Society of Hematology Annual Meeting and Exposition